Most Read Articles
20 May 2019

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

31 May 2019
Co-therapy with proton pump inhibitors (PPIs) in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease confers no benefit for upper gastrointestinal events but may reduce bleeding due to gastroduodenal lesions, a study has shown.
07 May 2019
Adding bismuth to a 14-day course of standard triple therapy with clarithromycin and amoxicillin leads to a high rate of Helicobacter pylori infection eradication, with an acceptable safety profile and level of adherence, according to a study.
Laura Kho Sui San , 29 May 2019
Anxiety becomes a pathological disorder when it occurs for no detectable reason, persists and interferes with daily activities like work performance and relationships.

Cyclosporin safe, effective for long-term autoimmune hepatitis treatment

30 May 2019
World Hepatitis Day (WHD) takes places every year on 28 July.

Cyclosporin (CSA) is safe and effective for long-term treatment of autoimmune hepatitis (AIH), a recent study has shown.

Researchers retrospectively assessed 20 young patients (median age at diagnosis, 9.5 years; 15 females) of whom 15 had classical AIH and five had AIH/autoimmune sclerosing cholangitis overlap syndrome. Patients were treated with CSA for a median duration of 6.3 years either alone or in combination with mycophenolate mofetil, azathioprine or prednisone.

After a median treatment period of 8.5 weeks, CSA resulted in 100-percent initial clinical and biochemical remission. After 8.6 years of follow-up, all patients were alive and had their native livers. Only one was listed for transplantation.

Of the 12 patients who received CSA as a first-line treatment, 10 reached complete remission at the end of follow-up. Four of these patients had had one or more relapse episodes. In comparison, there was one case each of treatment failure and incomplete response to treatment.

Of the eight patients who received CSA as second-line treatment, five achieved complete remission at the end of follow-up, two had treatment failure, and one had incomplete response.

In terms of safety, researchers reported hypertrichosis in 45 percent (n=9) of the participants, which resolved either spontaneously or after CSA was tapered off. Eleven patients (55 percent) displayed gingival hyperplasia, all cases of which likewise resolved after dosage reduction.

Estimated glomerular filtration rate at the beginning of CSA treatment and at the end of follow-up were statistically comparable (p=0.41), indicating the long-term safety of treatment.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
20 May 2019

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

31 May 2019
Co-therapy with proton pump inhibitors (PPIs) in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease confers no benefit for upper gastrointestinal events but may reduce bleeding due to gastroduodenal lesions, a study has shown.
07 May 2019
Adding bismuth to a 14-day course of standard triple therapy with clarithromycin and amoxicillin leads to a high rate of Helicobacter pylori infection eradication, with an acceptable safety profile and level of adherence, according to a study.
Laura Kho Sui San , 29 May 2019
Anxiety becomes a pathological disorder when it occurs for no detectable reason, persists and interferes with daily activities like work performance and relationships.